for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

REFILE-BRIEF-Blueprint Medicines Expects Decision From European Commission On PDGFRA D842V GIST Indication In Q3 2020

(Corrects to add source)

Jan 9 (Reuters) - Blueprint Medicines Corp:

* BLUEPRINT MEDICINES - CONTINUES TO PURSUE CONDITIONAL MARKETING AUTHORIZATION FOR AVAPRITINIB FOR PDGFRA D842V MUTANT GIST IN EU

* BLUEPRINT MEDICINES - ANTICIPATES DECISION FROM EUROPEAN COMMISSION ON PDGFRA D842V GIST INDICATION IN Q3 2020 Source text: [bit.ly/306obBp] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up